Preclinical Nasal Spray Boosts Mucosal Defense and Blocks Allergic Responses in Mice

An intranasal formulation described as GLA-3M-052-LS+OVA was reported in a Stanford Medicine mouse study to “supercharge” airway and mucosal defenses, with the write-up describing broad protection against diverse respiratory threats alongside an allergy-related signal in the same animal models. The approach is framed as a type of “universal” strategy that is not aimed at a single virus or bacterium, but instead at sustaining readiness in the lungs. The formulation is presented as an experimental, preclinical intervention evaluated in mice rather than in humans.

Vaccinated mice challenged with SARS‑CoV‑2 and other coronaviruses had markedly lower viral burden in the lung, including an approximately 700-fold reduction in viral levels, and that these animals showed less severe illness with less weight loss and improved survival compared with unvaccinated mice. Influenza is mentioned as a potential future target for a nasal-spray approach, but the reported mouse challenge data focus on coronaviruses, selected bacterial pathogens, and a house dust mite allergen model. Beyond viruses, the report states that the same intranasal approach was tested in bacterial pneumonia models involving Staphylococcus aureus and Acinetobacter baumannii, with vaccinated mice described as being protected from these respiratory infections. Across these challenge settings, the summary presents the findings as cross-pathogen protection localized to the lung in mouse experiments.

Durability is presented as part of the reported effect, with the summary stating that protection persisted for months in the animal models and describing protection for at least three months in vaccinated mice. In a separate set of experiments on allergic airway outcomes, the summary reports that investigators exposed mice to house dust mite material and assessed allergic responses in the airways. Unvaccinated mice were described as developing a strong Th2-type allergic response with mucus accumulation, while vaccinated mice were reported to have a much weaker Th2 response and clearer airways. In aggregate, the summary links the intranasal formulation to persistence over time and attenuation of allergic airway reactions in mice.

The formulation is designed to imitate communication signals exchanged by immune cells during infection, with the authors describing this as a way to coordinate innate and adaptive immunity and keep innate defenses in the lung activated longer than is typical. As presented in the report, this design includes a combination of toll-like receptor stimuli with an antigen component intended to draw T cells into the lungs and sustain the heightened innate state. Looking ahead, the investigators are quoted as planning to begin human testing with a Phase I safety trial as the next stated step.